These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 39090129)

  • 1. MHC-I-presented non-canonical antigens expand the cancer immunotherapy targets in acute myeloid leukemia.
    Cai Y; Li D; Lv D; Yu J; Ma Y; Jiang T; Ding N; Liu Z; Li Y; Xu J
    Sci Data; 2024 Aug; 11(1):831. PubMed ID: 39090129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes.
    Ehx G; Larouche JD; Durette C; Laverdure JP; Hesnard L; Vincent K; Hardy MP; Thériault C; Rulleau C; Lanoix J; Bonneil E; Feghaly A; Apavaloaei A; Noronha N; Laumont CM; Delisle JS; Vago L; Hébert J; Sauvageau G; Lemieux S; Thibault P; Perreault C
    Immunity; 2021 Apr; 54(4):737-752.e10. PubMed ID: 33740418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy.
    Berlin C; Kowalewski DJ; Schuster H; Mirza N; Walz S; Handel M; Schmid-Horch B; Salih HR; Kanz L; Rammensee HG; Stevanović S; Stickel JS
    Leukemia; 2015 Mar; 29(3):647-59. PubMed ID: 25092142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia.
    Goswami M; Hourigan CS
    Curr Drug Targets; 2017; 18(3):296-303. PubMed ID: 25706110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
    Newey A; Griffiths B; Michaux J; Pak HS; Stevenson BJ; Woolston A; Semiannikova M; Spain G; Barber LJ; Matthews N; Rao S; Watkins D; Chau I; Coukos G; Racle J; Gfeller D; Starling N; Cunningham D; Bassani-Sternberg M; Gerlinger M
    J Immunother Cancer; 2019 Nov; 7(1):309. PubMed ID: 31735170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.
    Anguille S; Van Tendeloo VF; Berneman ZN
    Leukemia; 2012 Oct; 26(10):2186-96. PubMed ID: 22652755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides.
    Bedran G; Gasser HC; Weke K; Wang T; Bedran D; Laird A; Battail C; Zanzotto FM; Pesquita C; Axelson H; Rajan A; Harrison DJ; Palkowski A; Pawlik M; Parys M; O'Neill JR; Brennan PM; Symeonides SN; Goodlett DR; Litchfield K; Fahraeus R; Hupp TR; Kote S; Alfaro JA
    Cancer Immunol Res; 2023 Jun; 11(6):747-762. PubMed ID: 36961404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
    Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
    Leung WK; Torres Chavez AG; French-Kim M; Shafer P; Mamonkin M; Hill LC; Kuvalekar M; Velazquez Y; Watanabe A; Watanabe N; Hoyos V; Lulla P; Leen AM
    Blood; 2024 Apr; 143(17):1726-1737. PubMed ID: 38241630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.
    Narayan R; Olsson N; Wagar LE; Medeiros BC; Meyer E; Czerwinski D; Khodadoust MS; Zhang L; Schultz L; Davis MM; Elias JE; Levy R
    PLoS One; 2019; 14(7):e0219547. PubMed ID: 31291378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer.
    Ouspenskaia T; Law T; Clauser KR; Klaeger S; Sarkizova S; Aguet F; Li B; Christian E; Knisbacher BA; Le PM; Hartigan CR; Keshishian H; Apffel A; Oliveira G; Zhang W; Chen S; Chow YT; Ji Z; Jungreis I; Shukla SA; Justesen S; Bachireddy P; Kellis M; Getz G; Hacohen N; Keskin DB; Carr SA; Wu CJ; Regev A
    Nat Biotechnol; 2022 Feb; 40(2):209-217. PubMed ID: 34663921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Approaches to Acute Myeloid Leukemia Immunotherapy.
    Beyar-Katz O; Gill S
    Clin Cancer Res; 2018 Nov; 24(22):5502-5515. PubMed ID: 29903894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.
    Khodadoust MS; Olsson N; Wagar LE; Haabeth OA; Chen B; Swaminathan K; Rawson K; Liu CL; Steiner D; Lund P; Rao S; Zhang L; Marceau C; Stehr H; Newman AM; Czerwinski DK; Carlton VE; Moorhead M; Faham M; Kohrt HE; Carette J; Green MR; Davis MM; Levy R; Elias JE; Alizadeh AA
    Nature; 2017 Mar; 543(7647):723-727. PubMed ID: 28329770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solving an MHC allele-specific bias in the reported immunopeptidome.
    Klatt MG; Mack KN; Bai Y; Aretz ZEH; Nathan LI; Mun SS; Dao T; Scheinberg DA
    JCI Insight; 2020 Oct; 5(19):. PubMed ID: 32897882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Greiner J; Döhner H; Schmitt M
    Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advance in antigen-specific immunotherapy for acute myeloid leukemia.
    Kadowaki N; Kitawaki T
    Clin Dev Immunol; 2011; 2011():104926. PubMed ID: 22028726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies.
    Pandey K; Mifsud NA; Lim Kam Sian TCC; Ayala R; Ternette N; Ramarathinam SH; Purcell AW
    Mol Immunol; 2020 Jul; 123():7-17. PubMed ID: 32387766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing neoantigens for personalized cancer immunotherapy.
    Capietto AH; Jhunjhunwala S; Delamarre L
    Curr Opin Immunol; 2017 Jun; 46():58-65. PubMed ID: 28478383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.